- Home
- LYEL
as 04-18-2025 1:39pm EST
Lyell Immunopharma Inc is a clinical-stage cell therapy company. It has a pipeline of product candidates for patients with solid tumors utilizing ex vivo genetic and epigenetic T-cell reprogramming technologies. The company's product pipeline includes, LYL797, LYL119, LYL845 among others.
| Founded: | 2018 | Country: | United States |
| Employees: | N/A | City: | SOUTH SAN FRANCISCO |
| Market Cap: | 207.7M | IPO Year: | 2021 |
| Target Price: | $1.00 | AVG Volume (30 days): | 752.1K |
| Analyst Decision: | Sell | Number of Analysts: | 2 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.31 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.39 - $2.88 | Next Earning Date: | 05-05-2025 |
| Revenue: | $61,000 | Revenue Growth: | -53.08% |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of Lyell Immunopharma Inc. (LYEL)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| BRAWLEY OTIS W | LYEL | Director | Mar 31 '25 | Buy | $0.56 | 35,640 | $19,958.40 | 35,640 | |
| Ramachandra Sumant | LYEL | Director | Mar 21 '25 | Buy | $0.58 | 200,000 | $115,220.00 | 200,000 | |
| Newton Charles W. | LYEL | Chief Financial Officer | Mar 17 '25 | Buy | $0.56 | 200,000 | $111,620.00 | 200,000 | |
| Seely Lynn | LYEL | President and CEO | Mar 14 '25 | Buy | $0.61 | 175,000 | $106,190.00 | 712,500 | |
| Klausner Richard | LYEL | Director | Mar 14 '25 | Buy | $0.60 | 158,000 | $94,942.20 | 843,365 |
Latest Lyell Immunopharma Inc. News
LYEL Breaking Stock News: Dive into LYEL Ticker-Specific Updates for Smart Investing
MT Newswires
4 days ago
Lyell Immunopharma Says its Relapsed Large B-Cell Lymphoma Therapy Receives US FDA's REMAT Designation
GlobeNewswire
4 days ago
Lyell Immunopharma Receives Regenerative Medicine Advanced Therapy (RMAT) Designation for LYL314 for the Treatment of Relapsed and/or Refractory Large B-Cell Lymphoma
Insider Monkey
22 days ago
Is Lyell Immunopharma, Inc. (LYEL) the Cheapest Stock Insiders Are Buying In March?
Simply Wall St.
a month ago
Favourable Signals For Lyell Immunopharma: Numerous Insiders Acquired Stock
GlobeNewswire
a month ago
Lyell Immunopharma Reports Business Highlights and Financial Results for the Fourth Quarter and Full Year 2024
GlobeNewswire
2 months ago
Lyell Immunopharma Announces Participation in Upcoming Investor Conferences
Simply Wall St.
3 months ago
Lyell Immunopharma, Inc. (NASDAQ:LYEL) has caught the attention of institutional investors who hold a sizeable 46% stake
Zacks
3 months ago
Lyell Immunopharma (LYEL) Upgraded to Strong Buy: Here's Why
Compare LYEL vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "LYEL Lyell Immunopharma Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.